Literature DB >> 29266381

Bone biopsy protocol for advanced prostate cancer in the era of precision medicine.

Verena Sailer1,2, Marc H Schiffman3, Myriam Kossai1,2, Joanna Cyrta1,2, Shaham Beg1,2, Brian Sullivan3, Bradley B Pua3, Kyungmouk Steve Lee3, Adam D Talenfeld3, David M Nanus4,5, Scott T Tagawa4,5, Brian D Robinson1,2, Rema A Rao1,2, Chantal Pauli1,2, Rohan Bareja2,6, Luis S Beltran7, Alexandros Sigaras2, Kenneth Wa Eng2,4,8, Olivier Elemento1,2,6,8, Andrea Sboner1,2,6, Mark A Rubin1,2,4, Himisha Beltran2,4,5, Juan Miguel Mosquera1,2.   

Abstract

BACKGROUND: Metastatic biopsies are increasingly being performed in patients with advanced prostate cancer to search for actionable targets and/or to identify emerging resistance mechanisms. Due to a predominance of bone metastases and their sclerotic nature, obtaining sufficient tissue for clinical and genomic studies is challenging.
METHODS: Patients with prostate cancer bone metastases were enrolled between February 2013 and March 2017 on an institutional review board-approved protocol for prospective image-guided bone biopsy. Bone biopsies and blood clots were collected fresh. Compact bone was subjected to formalin with a decalcifying agent for diagnosis; bone marrow and blood clots were frozen in optimum cutting temperature formulation for next-generation sequencing. Frozen slides were cut from optimum cutting temperature cryomolds and evaluated for tumor histology and purity. Tissue was macrodissected for DNA and RNA extraction, and whole-exome sequencing and RNA sequencing were performed.
RESULTS: Seventy bone biopsies from 64 patients were performed. Diagnostic material confirming prostate cancer was successful in 60 of 70 cases (85.7%). The median DNA/RNA yield was 25.5 ng/μL and 16.2 ng/μL, respectively. Whole-exome sequencing was performed successfully in 49 of 60 cases (81.7%), with additional RNA sequencing performed in 20 of 60 cases (33.3%). Recurrent alterations were as expected, including those involving the AR, PTEN, TP53, BRCA2, and SPOP genes.
CONCLUSIONS: This prostate cancer bone biopsy protocol ensures a valuable source for high-quality DNA and RNA for tumor sequencing and may be used to detect actionable alterations and resistance mechanisms in patients with bone metastases. Cancer 2018;124:1008-15.
© 2017 American Cancer Society. © 2017 American Cancer Society.

Entities:  

Keywords:  DNA; RNA; biopsy; bone metastases; next-generation sequencing (NGS); precision medicine; prostate cancer

Mesh:

Year:  2017        PMID: 29266381      PMCID: PMC5821525          DOI: 10.1002/cncr.31173

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  25 in total

1.  Bone marrow biopsy: RNA isolation with expression profiling in men with metastatic castration-resistant prostate cancer--factors affecting diagnostic success.

Authors:  Charles E Spritzer; P Diana Afonso; Emily N Vinson; James D Turnbull; Karla K Morris; Adam Foye; John F Madden; Kingshuk Roy Choudhury; Phillip G Febbo; Daniel J George
Journal:  Radiology       Date:  2013-10-28       Impact factor: 11.105

2.  Library Quantification: Fluorometric Quantitation of Double-Stranded or Single-Stranded DNA Samples Using the Qubit System.

Authors:  Elaine Mardis; W Richard McCombie
Journal:  Cold Spring Harb Protoc       Date:  2017-06-01

Review 3.  Fluorodeoxyglucose positron emission tomography/magnetic resonance imaging: current status, future aspects.

Authors:  Rajan Rakheja; Hersh Chandarana; Fabio Ponzo; Alexandra L Seltzer; Luis S Beltran; Christian Geppert; Kent P Friedman
Journal:  PET Clin       Date:  2013-12-27

4.  Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.

Authors:  Himisha Beltran; Kenneth Eng; Juan Miguel Mosquera; Alexandros Sigaras; Alessandro Romanel; Hanna Rennert; Myriam Kossai; Chantal Pauli; Bishoy Faltas; Jacqueline Fontugne; Kyung Park; Jason Banfelder; Davide Prandi; Neel Madhukar; Tuo Zhang; Jessica Padilla; Noah Greco; Terra J McNary; Erick Herrscher; David Wilkes; Theresa Y MacDonald; Hui Xue; Vladimir Vacic; Anne-Katrin Emde; Dayna Oschwald; Adrian Y Tan; Zhengming Chen; Colin Collins; Martin E Gleave; Yuzhuo Wang; Dimple Chakravarty; Marc Schiffman; Robert Kim; Fabien Campagne; Brian D Robinson; David M Nanus; Scott T Tagawa; Jenny Z Xiang; Agata Smogorzewska; Francesca Demichelis; David S Rickman; Andrea Sboner; Olivier Elemento; Mark A Rubin
Journal:  JAMA Oncol       Date:  2015-07       Impact factor: 31.777

5.  Cancer Statistics, 2017.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2017-01-05       Impact factor: 508.702

6.  Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer.

Authors:  Susan Halabi; William Kevin Kelly; Hua Ma; Haojin Zhou; Nicole C Solomon; Karim Fizazi; Catherine M Tangen; Mark Rosenthal; Daniel P Petrylak; Maha Hussain; Nicholas J Vogelzang; Ian M Thompson; Kim N Chi; Johann de Bono; Andrew J Armstrong; Mario A Eisenberger; Abderrahim Fandi; Shaoyi Li; John C Araujo; Christopher J Logothetis; David I Quinn; Michael J Morris; Celestia S Higano; Ian F Tannock; Eric J Small
Journal:  J Clin Oncol       Date:  2016-03-07       Impact factor: 44.544

7.  The Molecular Taxonomy of Primary Prostate Cancer.

Authors: 
Journal:  Cell       Date:  2015-11-05       Impact factor: 41.582

8.  Integrative clinical genomics of advanced prostate cancer.

Authors:  Dan Robinson; Eliezer M Van Allen; Yi-Mi Wu; Nikolaus Schultz; Robert J Lonigro; Juan-Miguel Mosquera; Bruce Montgomery; Mary-Ellen Taplin; Colin C Pritchard; Gerhardt Attard; Himisha Beltran; Wassim Abida; Robert K Bradley; Jake Vinson; Xuhong Cao; Pankaj Vats; Lakshmi P Kunju; Maha Hussain; Felix Y Feng; Scott A Tomlins; Kathleen A Cooney; David C Smith; Christine Brennan; Javed Siddiqui; Rohit Mehra; Yu Chen; Dana E Rathkopf; Michael J Morris; Stephen B Solomon; Jeremy C Durack; Victor E Reuter; Anuradha Gopalan; Jianjiong Gao; Massimo Loda; Rosina T Lis; Michaela Bowden; Stephen P Balk; Glenn Gaviola; Carrie Sougnez; Manaswi Gupta; Evan Y Yu; Elahe A Mostaghel; Heather H Cheng; Hyojeong Mulcahy; Lawrence D True; Stephen R Plymate; Heidi Dvinge; Roberta Ferraldeschi; Penny Flohr; Susana Miranda; Zafeiris Zafeiriou; Nina Tunariu; Joaquin Mateo; Raquel Perez-Lopez; Francesca Demichelis; Brian D Robinson; Marc Schiffman; David M Nanus; Scott T Tagawa; Alexandros Sigaras; Kenneth W Eng; Olivier Elemento; Andrea Sboner; Elisabeth I Heath; Howard I Scher; Kenneth J Pienta; Philip Kantoff; Johann S de Bono; Mark A Rubin; Peter S Nelson; Levi A Garraway; Charles L Sawyers; Arul M Chinnaiyan
Journal:  Cell       Date:  2015-05-21       Impact factor: 41.582

9.  SNP panel identification assay (SPIA): a genetic-based assay for the identification of cell lines.

Authors:  Francesca Demichelis; Heidi Greulich; Jill A Macoska; Rameen Beroukhim; William R Sellers; Levi Garraway; Mark A Rubin
Journal:  Nucleic Acids Res       Date:  2008-02-27       Impact factor: 16.971

10.  Unraveling the clonal hierarchy of somatic genomic aberrations.

Authors:  Davide Prandi; Sylvan C Baca; Alessandro Romanel; Christopher E Barbieri; Juan-Miguel Mosquera; Jacqueline Fontugne; Himisha Beltran; Andrea Sboner; Levi A Garraway; Mark A Rubin; Francesca Demichelis
Journal:  Genome Biol       Date:  2014-08-26       Impact factor: 13.583

View more
  15 in total

Review 1.  Bone and Soft-Tissue Biopsies: What You Need to Know.

Authors:  Dimitrios K Filippiadis; George Charalampopoulos; Argyro Mazioti; Kalliopi Keramida; Alexis Kelekis
Journal:  Semin Intervent Radiol       Date:  2018-11-05       Impact factor: 1.513

2.  Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer.

Authors:  Verena Sailer; Kenneth Wa Eng; Tuo Zhang; Rohan Bareja; David J Pisapia; Alexandros Sigaras; Bhavneet Bhinder; Alessandro Romanel; David Wilkes; Evan Sticca; Joanna Cyrta; Rema Rao; Sheena Sahota; Chantal Pauli; Shaham Beg; Samaneh Motanagh; Myriam Kossai; Jacqueline Fontunge; Loredana Puca; Hanna Rennert; Jenny Zhaoying Xiang; Noah Greco; Rob Kim; Theresa Y MacDonald; Terra McNary; Mirjam Blattner-Johnson; Marc H Schiffman; Bishoy M Faltas; Jeffrey P Greenfield; David Rickman; Eleni Andreopoulou; Kevin Holcomb; Linda T Vahdat; Douglas S Scherr; Koen van Besien; Christopher E Barbieri; Brian D Robinson; Howard Alan Fine; Allyson J Ocean; Ana Molina; Manish A Shah; David M Nanus; Qiulu Pan; Francesca Demichelis; Scott T Tagawa; Wei Song; Juan Miguel Mosquera; Andrea Sboner; Mark A Rubin; Olivier Elemento; Himisha Beltran
Journal:  JCO Precis Oncol       Date:  2019-09-20

3.  A Novel Overall Survival Prediction Signature Based on Comprehensive Research in Prostate Cancer Bone Metastases.

Authors:  Konghe Hu; Xinyue Hu; Yang Duan; Wenqiang Li; Jing Qian; Junjie Chen
Journal:  Front Med (Lausanne)       Date:  2022-06-16

4.  Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 Study.

Authors:  Andrea Loehr; Akash Patnaik; David Campbell; Jeremy Shapiro; Alan H Bryce; Ray McDermott; Brieuc Sautois; Nicholas J Vogelzang; Richard M Bambury; Eric Voog; Jingsong Zhang; Josep M Piulats; Arif Hussain; Charles J Ryan; Axel S Merseburger; Gedske Daugaard; Axel Heidenreich; Karim Fizazi; Celestia S Higano; Laurence E Krieger; Cora N Sternberg; Simon P Watkins; Darrin Despain; Andrew D Simmons; Melanie Dowson; Tony Golsorkhi; Simon Chowdhury; Wassim Abida
Journal:  Clin Cancer Res       Date:  2021-10-01       Impact factor: 13.801

5.  Phase II Multicenter Study of Enzalutamide in Metastatic Castration-Resistant Prostate Cancer to Identify Mechanisms Driving Resistance.

Authors:  Rana R McKay; Lucia Kwak; Jett P Crowdis; Jamie M Sperger; Shuang G Zhao; Wanling Xie; Lillian Werner; Rosina T Lis; Zhenwei Zhang; Xiao X Wei; Joshua M Lang; Eliezer M Van Allen; Rupal S Bhatt; Evan Y Yu; Peter S Nelson; Glenn J Bubley; R Bruce Montgomery; Mary-Ellen Taplin
Journal:  Clin Cancer Res       Date:  2021-04-13       Impact factor: 12.531

6.  Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms.

Authors:  Hanna Tukachinsky; Russell W Madison; Jon H Chung; Ole V Gjoerup; Eric A Severson; Lucas Dennis; Bernard J Fendler; Samantha Morley; Lei Zhong; Ryon P Graf; Jeffrey S Ross; Brian M Alexander; Wassim Abida; Simon Chowdhury; Charles J Ryan; Karim Fizazi; Tony Golsorkhi; Simon P Watkins; Andrew Simmons; Andrea Loehr; Jeffrey M Venstrom; Geoffrey R Oxnard
Journal:  Clin Cancer Res       Date:  2021-02-08       Impact factor: 13.801

7.  Pharmacodynamic study of radium-223 in men with bone metastatic castration resistant prostate cancer.

Authors:  Andrew J Armstrong; Santosh Gupta; Patrick Healy; Gabor Kemeny; Beth Leith; Michael R Zalutsky; Charles Spritzer; Catrin Davies; Colin Rothwell; Kathryn Ware; Jason A Somarelli; Kris Wood; Thomas Ribar; Paraskevi Giannakakou; Jiaren Zhang; Drew Gerber; Monika Anand; Wen-Chi Foo; Susan Halabi; Simon G Gregory; Daniel J George
Journal:  PLoS One       Date:  2019-05-28       Impact factor: 3.240

8.  A Prospective Correlation of Tissue Histopathology With Nucleic Acid Yield in Metastatic Castration-Resistant Prostate Cancer Biopsy Specimens.

Authors:  Rafael E Jimenez; Thomas D Atwell; Hughes Sicotte; Bruce Eckloff; Liguo Wang; Poulami Barman; Jason P Sinnwell; Patrick W Eiken; Brendan P McMenomy; Winston Tan; Liewei Wang; Rachel E Carlson; Manish Kohli
Journal:  Mayo Clin Proc Innov Qual Outcomes       Date:  2019-02-26

9.  Accelerating precision medicine in metastatic prostate cancer.

Authors:  Joaquin Mateo; Rana McKay; Wassim Abida; Rahul Aggarwal; Joshi Alumkal; Ajjai Alva; Felix Feng; Xin Gao; Julie Graff; Maha Hussain; Fatima Karzai; Bruce Montgomery; William Oh; Vaibhav Patel; Dana Rathkopf; Matthew Rettig; Nikolaus Schultz; Matthew Smith; David Solit; Cora Sternberg; Eliezer Van Allen; David VanderWeele; Jake Vinson; Howard R Soule; Arul Chinnaiyan; Eric Small; Jonathan W Simons; William Dahut; Andrea K Miyahira; Himisha Beltran
Journal:  Nat Cancer       Date:  2020-11-17

10.  Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis.

Authors:  Markus Mayrhofer; Bram De Laere; Tom Whitington; Peter Van Oyen; Christophe Ghysel; Jozef Ampe; Piet Ost; Wim Demey; Lucien Hoekx; Dirk Schrijvers; Barbara Brouwers; Willem Lybaert; Els Everaert; Daan De Maeseneer; Michiel Strijbos; Alain Bols; Karen Fransis; Steffi Oeyen; Pieter-Jan van Dam; Gert Van den Eynden; Annemie Rutten; Markus Aly; Tobias Nordström; Steven Van Laere; Mattias Rantalainen; Prabhakar Rajan; Lars Egevad; Anders Ullén; Jeffrey Yachnin; Luc Dirix; Henrik Grönberg; Johan Lindberg
Journal:  Genome Med       Date:  2018-11-21       Impact factor: 11.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.